Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

BACKGROUND: Long-term nucleos(t)ide analogue (NA) treatment can reverse liver fibrosis in chronic hepatitis B (CHB), but its effect on fibrosis regression remains limited. Biejia-Ruangan (BR) has been approved in China as an antifibrotic traditional Chinese medicine drug in patients with chronic liv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rong, Guanghua, Chen, Yongping, Yu, Zujiang, Li, Qin, Bi, Jingfeng, Tan, Lin, Xiang, Dedong, Shang, Qinghua, Lei, Chunliang, Chen, Liang, Hu, Xiaoyu, Wang, Jing, Liu, Huabao, Lu, Wei, Chen, Yan, Dong, Zheng, Bai, Wenlin, Yoshida, Eric M, Mendez-Sanchez, Nahum, Hu, Ke-Qin, Qi, Xingshun, Yang, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921993/
https://www.ncbi.nlm.nih.gov/pubmed/32437567
http://dx.doi.org/10.1093/infdis/jiaa266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921993/
https://www.ncbi.nlm.nih.gov/pubmed/32437567
http://dx.doi.org/10.1093/infdis/jiaa266

Ejemplares similares